Russian SARS2 Vaccine safe, 92% effective for even 60s plus
“The efficacy looks good, including in the over 60s,” said Danny Altmann, a professor of immunology at Imperial College London. “It’s good to have another addition to the global arsenal.”
2,144 Volunteers over 60 in the Sputnik V trial proved the vaccine to be 91.8% effective. There were no serious side-effects reported that could be associated with the vaccine a detailed peer-reviewed report in The Lancet said.
The Sputnik V vaccine can be stored in refrigerators and thus easily distributed and it will require two distinctly different doses, twenty-one days apart.
“The Sputnik V vaccine uses a heterologous recombinant adenovirus approach using adenovirus 26 (Ad26) and adenovirus 5 (Ad5) as vectors for the expression of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The use of two varying serotypes, which are given 21 days apart, is intended to overcome any pre-existing adenovirus immunity in the population,” notes the Lancet.
Read detailed medical evaluation of the Phase III trials from “Sputnik V COVID-19 vaccine candidate appears safe and effective.”
Russian citizens have already been offered the vaccine since the start of the year. Frontline workers in Russia were given the vaccine last year.
Current Global COVID-19 Statistics (January 27, 2022)
253 Locales report 362,608,011 COVID-19 cases of which there are 65,199,344 active cases, therefore 291,745,904 recoveries and 5,662,763 fatalities.
GMT 2022-01-27 01:39
Data reported should be in accordance with the applied case definitions and testing strategies in each locale as their governments report daily or from time to time.
All data researched and published by The RINJ Foundation and partners in CSPaC.
©The RINJ Foundation 2020-2022-01-27T01:39:12Z #Singapore-SK-HUK-77
RINJ is with Civil Society Solidarity Partners against COVID-19.
SARS2 Update 2022-01-27 01:39 GMT
- Global Population: 7,871,660,945
- 253 Regions reported 362,608,011 cases
- 65,199,344 cases active
- 5,662,763 people reported killed by COVID-19
- 1.56% is current Case Fatality Rate (CFR)
- 291,745,904 survived COVID-19
- 23.63% of all humans (1,860,179,096) have been infected
- 0.70% Global estimated inferred average Infection Fatality Rate (IFR)
(influenza is .1% or 6 per 100k (2019))
- 12,961,781 Total deaths (estimated actual) including errors, unexpected deaths with pneumonia indications with no history, and unreported likely-cause excess deaths such as people who never went to a hospital but had COVID-19 indications but never tested.
- 112.59% of the USA may have been infected including reported + estimated unreported mild and estimated asymptomatic (374,297,671.17) persons, some of whom may not have been ill in their first course of the disease, but could have spread the disease.
- 1.22% is USA current Case Fatality Rate (CFR) &
- 0.27% is estimated inferred average Infection Fatality Rate (IFR)
- 1,010,604 estimated total COVID-19 deaths including unreported likely-cause excess deaths. According to projections of IHME, IHME calculation of excess deaths is higher than what CSPaC is showing.
The American Epicenter has 42.36 % of global 'active' cases (27,618,666 USA / 65,199,344 Global), people infected with COVID-19 now.
Below: CSPAC estimated 2022-01-27 00:36 GMT COVID-19 data for India.
EPICENTER-2: India (40,369,585)
Note: India's reported death sum and cured data are widely seen among epidemiologists and biostatisticians as unreliable. For example, 2,704,460 is CSPAC estimated sum of deaths while India reports 491,729, creating the largest discepency in the world. India might only report hospital tested cases. Sources among hundreds of nurses and other medical practitioners provide a picture that in summary concludes most cases never present in a hospital especially in northern provinces where health care is less available and utilization is low anyway because of poverty, hence most people die at home in India. This theory could explain discrepancies between reported data and algorithmic estimates.
Data collected and reported by: Civil Society Solidarity Partners against COVID-19